Prescription Drugs

This annual survey of employers provides a detailed look at trends in employer-sponsored health coverage, including premiums, worker contributions, cost-sharing provisions, offer rates, and more. This year’s report also looks at how employers are addressing a growing need for mental health services.

KFF has conducted this annual survey since 1999. The archives include surveys conducted in partnership with the Health Research and Education Trust through 2017 and a small business supplement of the 1998 survey conducted by KFF. The survey was previously conducted by KPMG from 1991–1998 and the Health Insurance Association…

Half of Large Employers See Growing Demand for Mental Health Services; 3 in 10 Say Their Plan Has Too Few Behavioral Health Providers to Ensure Timely Access to Care Annual family premiums for employer-sponsored health insurance average $22,463 this year, similar to last year ($22,221), the 2022 benchmark KFF Employer…

This charticle draws on recent KFF poll findings to provide an in-depth look at the public’s attitudes toward prescription drugs and their prices. Results include Americans’ opinions on drug affordability, pharmaceutical companies, and various potential measures that could lower prices.

This fact sheet includes the latest information and data about the Medicare Part D prescription drug benefit, including current plan information, the standard benefit parameters, low-income assistance, the latest available enrollment data, and Part D program spending and financing. It also highlights upcoming changes to Part D under the Inflation Reduction Act.

Few Voters Know About the Medicare Drug Provisions in the Inflation Reduction Act, Though Seniors are More Aware and Would Be Likely to Vote for Candidates Who Support Them About a month ahead of the 2022 midterm election, abortion continues to grow as a motivating issue for voters, especially among…

Leading up to the November 2022 midterm elections, abortion access is motivating majorities of Democratic women, women under 50 and and Democratic voters in states with abortion bans. For older voters, some health care issues related to Medicare costs are resonating.

The recent passage of the Inflation Reduction Act of 2022 (IRA) includes a number of climate, tax, and health care provisions and prescription drug reforms. This policy watch explores the potential impacts of the Inflation Reduction Act on overall Medicaid spending as well as implications for Medicaid beneficiaries.

In this column for the JAMA Forum, KFF’s Larry Levitt explores the Medicare drug-price negotiation provisions and other significant drug-price changes in the Inflation Reduction Act and their potential to lead to further efforts to address health care costs.

As the 2022 mid-term elections approach, inflation and gas prices are on the top of voters’ minds. While health care prices have often risen faster than the rest of the economy, the prices for medical services are generally set in advance – often tied to the calendar year – creating…